NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011

By Joseph F. Finn Jr. C.p.a., PRNE
Sunday, May 1, 2011

WELLESLEY HILLS, Massachusetts, May 2, 2011 - On April 20, 2011, NMT Medical, Inc. ("NMT Medical") assigned all its
assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke &
Gayton, LLP to be liquidated for the benefit of NMT Medical creditors.

NMT Medical's intellectual property consists of:

    - CLOSURE I Clinical Trial Data;
    - MIST and MIST II Clinical Trial Data;
    - CardioSEAL(R), STARFlex(R), and BioSTAR(R) Technologies for Septal
      Defect Repair;
    - BioTREK(TM) Bioabsorbable Technology for Intracardiac Defect Closure,
    - Alternative Technologies for Intracardiac Defect Closure

The intellectual property, patents, etc. will be sold at a sealed bid
sale on Friday, June 10, 2011 at noon. Persons interested in bidding must
sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's
Office - jffinnjr@finnwarnkegayton.com or +1-781-237-8840. They will then
receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm Finn,
Warnke & Gayton (www.finnwarnkegayton.com), Certified Public
Accountants of Wellesley Hills, Massachusetts. He works primarily in the area
of management consulting for distressed enterprises, bankruptcy accounting
and related matters, such as assignee for the benefit of creditors and
liquidating agent for a corporation. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-five (35) years. His most recent
Assignments for the Benefit of Creditors in the biotech field include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc., EPIX
Pharmaceuticals, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at
+1-781-237-8840 or jffinnjr@finnwarnkegayton.com


will not be displayed